LRRK2 and Parkinson's Disease Cell Biology
LRRK2 和帕金森病细胞生物学
基本信息
- 批准号:7891269
- 负责人:
- 金额:$ 35.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-07-15 至 2012-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAmino AcidsAutopsyBiochemicalBiological AssayBrainCell FractionationCell modelCellsCellular biologyCo-ImmunoprecipitationsCognitionDataDepositionDiseaseEmotionsFutureGTP BindingGeneric DrugsGeneticHistological TechniquesHumanImmunofluorescence ImmunologicIn VitroLeadLewy BodiesLibrariesMethodsMovement DisordersMusMutationNerve DegenerationNeuronsPINK1 geneParkinson DiseasePathogenesisPathologyPathway interactionsPhosphotransferasesProtein Kinase InteractionProteinsResearch PersonnelRoleSeriesSignal TransductionSmall Interfering RNASubstantia nigra structureTertiary Protein StructureTestingTherapeuticTherapeutic InterventionTissuesToxic effectUbiquitinationYeastsalpha synucleindisease-causing mutationhuman SNCAIP proteinhuman tissueimprovedin vitro Assayleucine-rich repeat kinase 2mutantneuroprotectionneurotoxicityparkin gene/proteinprotein aggregateprotein aggregationresponsetherapeutic targetyeast two hybrid system
项目摘要
DESCRIPTION (provided by applicant): LRRK2 and Parkinson's disease cell biology Parkinson's disease is a disorder of movement, cognition and emotion, characterized neuropathologically by neuronal degeneration and deposits of protein aggregates termed Lewy bodies. While most cases are sporadic, rare genetic forms of the disease, caused by mutations in alpha-synuclein, parkin, DJ-1 and PINK1, are helping to elucidate pathogenesis. In previous studies, we have defined the role of alpha- synuclein protein interactions (including interactions with synphilin-1 and parkin) in PD-related cell biology. Mutations in leucine-rich repeat kinase 2 (LRRK2) have recently been found to cause autosomal dominant PD. Our overall hypothesis is that identifications of LRRK2 protein interactions will help elucidate pathogeneses of LRRK2 related PD, and possibly sporadic PD. We have identified interactions between LRRK2 and several other proteins, including parkin, synphilin-1, WSB-1 and CARD7. We have found that that mutant LRRK2 causes direct cellular toxicity, and have initial data that for at least some of the LRRK2 mutations, GTP binding and kinase activity are necessary for toxicity. In Specific Aim 1 we will identify LRRK2 interacting proteins using the yeast two-hybrid system and co-immunopreciptation from transfected cells, and define interaction domains of these proteins. In Specific Aim 2 we will study the LRRK2 interactions in expression studies in cells in culture, and in mouse and human tissue, including postmortem human sporadic and mutant LRRK2 PD tissue. We will study the role of these interactors in LRRK2 cellular toxicity, by using siRNA, and by modifying the interaction domains. In Specific Aim 3 we will determine whether LRRK2 kinase activity is critical for cell toxicity, and determine whether LRRK2 can phosphorylate the interactors-and if so, we will determine whether this has a role in toxicity. These studies will help define the role of LRRK2 and its interacting proteins in cellular pathogenesis related to PD, and potentially identify targets for future therapeutic interventions.
描述(由申请人提供):LRRK 2和帕金森病细胞生物学帕金森病是一种运动、认知和情感障碍,其神经病理学特征为神经元变性和称为Lewy小体的蛋白质聚集体沉积。虽然大多数病例是散发性的,但由α-突触核蛋白,parkin,DJ-1和PINK 1突变引起的罕见遗传形式的疾病有助于阐明发病机制。在以前的研究中,我们已经确定了α-突触核蛋白蛋白相互作用(包括与synphilin-1和parkin的相互作用)在PD相关细胞生物学中的作用。最近发现富含亮氨酸重复序列激酶2(LRRK 2)的突变可导致常染色体显性PD。我们的总体假设是,LRRK 2蛋白相互作用的鉴定将有助于阐明LRRK 2相关PD的发病机制,并可能是散发性PD。我们已经确定了LRRK 2和其他几种蛋白质之间的相互作用,包括parkin,synphilin-1,WSB-1和CARD 7。我们已经发现,突变LRRK 2导致直接的细胞毒性,并有初步的数据,至少一些LRRK 2突变,GTP结合和激酶活性是必要的毒性。在具体目标1中,我们将使用酵母双杂交系统和共免疫沉淀从转染细胞中鉴定LRRK 2相互作用蛋白,并定义这些蛋白的相互作用结构域。在特定目标2中,我们将在培养细胞以及小鼠和人体组织(包括死后散发性和突变型LRRK 2 PD组织)中的表达研究中研究LRRK 2相互作用。我们将研究这些相互作用在LRRK 2细胞毒性的作用,通过使用siRNA,并通过修改的相互作用域。在具体目标3中,我们将确定LRRK 2激酶活性是否对细胞毒性至关重要,并确定LRRK 2是否可以磷酸化相互作用物,如果是这样,我们将确定这是否在毒性中起作用。这些研究将有助于确定LRRK 2及其相互作用蛋白在与PD相关的细胞发病机制中的作用,并可能确定未来治疗干预的靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher A Ross其他文献
Neurodegenerative Diseases: Dentatorubral-pallidoluysian atrophy (DRPLA): model for Huntington's disease and other polyglutamine diseases
神经退行性疾病:齿状红核苍白球萎缩症 (DRPLA):亨廷顿病和其他多聚谷氨酰胺疾病的模型
- DOI:
- 发表时间:
2005 - 期刊:
- 影响因子:0
- 作者:
Christopher A Ross;L. Ellerby;Jonathan D. Wood;Federick C. Nucifora - 通讯作者:
Federick C. Nucifora
Transcription meets metabolism in neurodegeneration
转录在神经退行性变中与代谢相遇
- DOI:
10.1038/nm1106-1239 - 发表时间:
2006-11-01 - 期刊:
- 影响因子:50.000
- 作者:
Christopher A Ross;Leslie Michels Thompson - 通讯作者:
Leslie Michels Thompson
Protein aggregation and neurodegenerative disease
蛋白质聚集与神经退行性疾病
- DOI:
10.1038/nm1066 - 发表时间:
2004-07-01 - 期刊:
- 影响因子:50.000
- 作者:
Christopher A Ross;Michelle A Poirier - 通讯作者:
Michelle A Poirier
Neuronal signaling pathways: genetic insights into the pathophysiology of major mental illness
神经元信号通路:对重大精神疾病病理生理学的遗传学见解
- DOI:
10.1038/npp.2009.137 - 发表时间:
2009-12-10 - 期刊:
- 影响因子:7.100
- 作者:
Russell L Margolis;Christopher A Ross - 通讯作者:
Christopher A Ross
Christopher A Ross的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher A Ross', 18)}}的其他基金
LRRK2 and inflammasome pathway in Parkinson's disease
帕金森病中的 LRRK2 和炎症小体通路
- 批准号:
10292714 - 财政年份:2021
- 资助金额:
$ 35.52万 - 项目类别:
LRRK2 and inflammasome pathway in Parkinson's disease
帕金森病中的 LRRK2 和炎症小体通路
- 批准号:
10432114 - 财政年份:2021
- 资助金额:
$ 35.52万 - 项目类别:
LRRK2 and inflammasome pathway in Parkinson's disease
帕金森病中的 LRRK2 和炎症小体通路
- 批准号:
10640900 - 财政年份:2021
- 资助金额:
$ 35.52万 - 项目类别:
Immortalized Striatal Precursor Neurons as a Screenable Model of HD
永生化纹状体前体神经元作为 HD 的筛选模型
- 批准号:
10550333 - 财政年份:2018
- 资助金额:
$ 35.52万 - 项目类别:
Validation of Novel Pathogenic Htt Post-Translational Modifications (PTMs)
新型致病性 Htt 翻译后修饰 (PTM) 的验证
- 批准号:
9008084 - 财政年份:2014
- 资助金额:
$ 35.52万 - 项目类别:
Validation of Novel Pathogenic Htt Post-Translational Modifications (PTMs)
新型致病性 Htt 翻译后修饰 (PTM) 的验证
- 批准号:
9222822 - 财政年份:2014
- 资助金额:
$ 35.52万 - 项目类别:
Validation of Novel Pathogenic Post-Translational Modifications of Huntingtin, and of Modifying Enzymes as Therapeutic Targets for Huntington's Disease
亨廷顿蛋白的新型致病性翻译后修饰以及修饰酶作为亨廷顿病治疗靶点的验证
- 批准号:
10599877 - 财政年份:2014
- 资助金额:
$ 35.52万 - 项目类别:
Validation of Novel Pathogenic Htt Post-Translational Modifications (PTMs)
新型致病性 Htt 翻译后修饰 (PTM) 的验证
- 批准号:
8826197 - 财政年份:2014
- 资助金额:
$ 35.52万 - 项目类别:
Validation of Novel Pathogenic Htt Post-Translational Modifications (PTMs)
新型致病性 Htt 翻译后修饰 (PTM) 的验证
- 批准号:
8659881 - 财政年份:2014
- 资助金额:
$ 35.52万 - 项目类别:
Immortalized Human Strital Precursors as a Cell Model of HD
永生化人类骨骼前体作为 HD 细胞模型
- 批准号:
8533521 - 财政年份:2013
- 资助金额:
$ 35.52万 - 项目类别:
相似海外基金
Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
- 批准号:
BB/Y006380/1 - 财政年份:2024
- 资助金额:
$ 35.52万 - 项目类别:
Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
- 批准号:
24K17112 - 财政年份:2024
- 资助金额:
$ 35.52万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
- 批准号:
23K04668 - 财政年份:2023
- 资助金额:
$ 35.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
- 批准号:
23K06918 - 财政年份:2023
- 资助金额:
$ 35.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
$ 35.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
- 批准号:
2888395 - 财政年份:2023
- 资助金额:
$ 35.52万 - 项目类别:
Studentship
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
- 批准号:
2300890 - 财政年份:2023
- 资助金额:
$ 35.52万 - 项目类别:
Continuing Grant
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
- 批准号:
10761044 - 财政年份:2023
- 资助金额:
$ 35.52万 - 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
- 批准号:
10728925 - 财政年份:2023
- 资助金额:
$ 35.52万 - 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
- 批准号:
10757309 - 财政年份:2023
- 资助金额:
$ 35.52万 - 项目类别:














{{item.name}}会员




